4D Molecular Therapeutics, Inc. $FDMT Shares Bought by Acadian Asset Management LLC

Acadian Asset Management LLC boosted its position in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) by 1,103.4% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 400,606 shares of the company’s stock after acquiring an additional 367,317 shares during the period. Acadian Asset Management LLC owned about 0.86% of 4D Molecular Therapeutics worth $1,290,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Dynamic Technology Lab Private Ltd acquired a new position in shares of 4D Molecular Therapeutics during the first quarter worth $39,000. Y Intercept Hong Kong Ltd acquired a new position in shares of 4D Molecular Therapeutics during the 1st quarter worth about $41,000. AQR Capital Management LLC acquired a new position in shares of 4D Molecular Therapeutics during the 1st quarter worth about $46,000. Russell Investments Group Ltd. acquired a new position in shares of 4D Molecular Therapeutics during the 1st quarter worth about $63,000. Finally, Proficio Capital Partners LLC boosted its holdings in 4D Molecular Therapeutics by 26.0% in the first quarter. Proficio Capital Partners LLC now owns 25,195 shares of the company’s stock valued at $75,000 after purchasing an additional 5,195 shares in the last quarter. Institutional investors and hedge funds own 99.27% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently issued reports on FDMT shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a report on Saturday, September 13th. Chardan Capital restated a “buy” rating and issued a $25.00 target price on shares of 4D Molecular Therapeutics in a report on Tuesday, August 12th. Finally, Roth Capital lowered their target price on shares of 4D Molecular Therapeutics from $44.00 to $38.00 and set a “buy” rating for the company in a report on Tuesday, August 12th. Eight analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $30.40.

4D Molecular Therapeutics Price Performance

Shares of NASDAQ:FDMT opened at $6.66 on Thursday. 4D Molecular Therapeutics, Inc. has a 1-year low of $2.23 and a 1-year high of $17.41. The stock has a market cap of $311.02 million, a P/E ratio of -1.89 and a beta of 2.86. The firm has a fifty day moving average price of $5.85 and a 200 day moving average price of $4.40.

4D Molecular Therapeutics (NASDAQ:FDMT) last announced its earnings results on Monday, August 11th. The company reported ($0.98) earnings per share for the quarter, missing the consensus estimate of ($0.88) by ($0.10). 4D Molecular Therapeutics had a negative return on equity of 40.15% and a negative net margin of 594,375.81%.The business had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.52 million. Sell-side analysts expect that 4D Molecular Therapeutics, Inc. will post -2.84 EPS for the current fiscal year.

4D Molecular Therapeutics Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.